NKTX
Nkarta, Inc.
$1.80
-0.13
(-6.74%)
Mkt Cap
128.92M
Volume
1,751,036
52W Range
1.63-3.72
Sector
Healthcare
Beta
0.94
EPS (TTM)
-1.57 USD
P/E Ratio
-1.31
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 115,385 | 6.55M |
| Net Income | (104.08M) | (108.79M) | (117.50M) | (113.84M) | (86.08M) | (91.36M) | (21.08M) | (274,503) |
| EPS | -1.41 | -1.60 | -2.40 | -2.61 | -2.62 | -1.59 | -2.55 | -0.01 |
| Free Cash Flow | (89.91M) | (104.11M) | (114.31M) | (104.11M) | (72.95M) | (51.02M) | (20.30M) | (5.94M) |
| FCF / Share | -1.22 | -1.53 | -2.33 | -2.39 | -2.22 | -1.60 | -2.26 | -0.12 |
| Operating CF | (88.70M) | (99.70M) | (86.16M) | (57.00M) | (67.93M) | (43.51M) | (18.37M) | (5.18M) |
| Total Assets | 404.21M | 501.20M | 378.88M | 472.94M | 273.90M | 337.65M | 48.41M | 9.61M |
| Total Debt | 76.42M | 80.27M | 88.34M | 82.93M | 12.46M | 8.92M | 7.30M | 12.71M |
| Cash & Equiv | 39.63M | 27.87M | 31.04M | 37.49M | 60.82M | 96.69M | 20.61M | 7.87M |
| Book Value | 312.32M | 407.98M | 273.29M | 372.21M | 250.97M | 321.22M | (25.48M) | (5.40M) |
| Return on Equity | -0.33 | -0.27 | -0.43 | -0.31 | -0.34 | -0.28 | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (40.37M) | (27.83M) | (27.41M) | (21.71M) | (22.98M) | (31.98M) | (25.93M) | (28.34M) | (24.99M) | (29.52M) | (27.75M) | (25.64M) |
| EPS | -0.54 | -0.37 | -0.37 | -0.29 | -0.31 | -0.43 | -0.35 | -0.39 | -0.34 | -0.58 | -0.57 | -0.52 |
| Free Cash Flow | (24.41M) | (28.61M) | (22.21M) | (18.68M) | (18.89M) | (30.13M) | (25.85M) | (25.32M) | (24.25M) | (28.68M) | (30.16M) | (26.46M) |
| FCF / Share | -0.33 | -0.39 | -0.30 | -0.25 | -0.26 | -0.41 | -0.35 | -0.34 | -0.33 | -0.57 | -0.61 | -0.54 |
| Operating CF | (24.22M) | (28.20M) | (21.65M) | (18.69M) | (18.75M) | (29.61M) | (24.75M) | (24.55M) | (21.89M) | (28.51M) | (23.35M) | (20.27M) |
| Total Assets | 337.64M | 372.07M | 404.21M | 427.24M | 448.31M | 470.61M | 501.20M | 532.03M | 554.09M | 576.94M | 378.88M | 405.86M |
| Total Debt | 73.54M | 75.00M | 76.42M | 76.63M | 78.54M | 78.91M | 80.27M | 85.45M | 85.57M | 87.17M | 88.34M | 89.47M |
| Cash & Equiv | 24.96M | 27.36M | 39.63M | 60.11M | 53.41M | 52.60M | 27.87M | 56.96M | 120.40M | 250.28M | 31.04M | 38.26M |
| Book Value | 247.74M | 285.86M | 312.32M | 337.90M | 357.67M | 378.81M | 407.98M | 430.87M | 453.18M | 473.65M | 273.29M | 296.82M |
| Return on Equity | -0.16 | -0.10 | -0.09 | -0.06 | -0.06 | -0.08 | -0.06 | -0.07 | -0.06 | -0.06 | -0.10 | -0.09 |
NKTX News
Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance
Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance
Nkarta (NASDAQ:NKTX) Stock Falls 3.5% – Here’s Why
Nkarta to Participate in September Investor Conferences
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
6,300,212 Shares in Nkarta, Inc. $NKTX Acquired by BlackRock Inc.
Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
The $13 Million Company Teaching the Immune System to Hunt Cancer
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights